Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model

Tomoharu Miyashita, Furhawn A. Shah, Guy P. Marti, Jiaai Wang, Pramod Bonde, Michael K. Gibson, Tetsuo Ohta, Elizabeth A Montgomery, Mark D Duncan, John Harmon

Research output: Contribution to journalArticle

Abstract

Background: The role of proton pump inhibitors in Barrett's metaplasia and esophageal adenocarcinoma has been an area of controversy. Aims: We evaluated the effectiveness of the proton pump inhibitor rabeprazole as a chemoprevention agent in a surgical rat reflux model of esophageal cancer. Methods: The rat reflux model was created by performing a jejuno-esophagostomy on Sprague-Dawley rats. The surgery promoted the reflux of gastro-duodenal contents into the esophagus. Rabeprazole sodium (Eisai, Tokyo, Japan) was dissolved in 0.9% physiological saline to a desired concentration of 1.5% (W/V). Beginning 4 weeks post-surgery, all animals were administered either 0.2 ml per 100 g body weight injections of rabeprazole or equivalent injections of saline 3 days per week into the subcutaneous tissue of the back. Forty animals were killed 40 weeks after surgery and their esophagi were examined. Of these, 23 were included in the control group, while the remaining 17 were subjected to rabeprazole. Results: While 74% (17/23) of the controls developed esophageal cancer, animals administered rabeprazole had an incidence of cancer of 29% (5/17) (p <0.05, Fisher's exact test). Barrett's metaplasia was found on 100% (23/23) of the rats in the placebo group, but there was a protective effect in the rabeprazole group with 65% (11/17) of the rats displaying signs of Barrett's metaplasia (p <0.05, Fisher's exact test). All of the rats developed proliferative hyperplasia. Conclusions: Rabeprazole protected against the development of esophageal cancer in a clinically relevant surgical reflux model. Rabeprazole warrants further investigation for potential clinical use as a chemoprevention agent.

Original languageEnglish (US)
Pages (from-to)1309-1314
Number of pages6
JournalDigestive Diseases and Sciences
Volume56
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Rabeprazole
Anatomic Models
Esophageal Neoplasms
Barrett Esophagus
Proton Pump Inhibitors
Chemoprevention
Esophagus
Esophagostomy
Duodenogastric Reflux
Injections
Tokyo
Subcutaneous Tissue
Hyperplasia
Sprague Dawley Rats
Japan
Adenocarcinoma
Placebos
Body Weight
Control Groups

Keywords

  • Barrett's metaplasia
  • Cancer prevention
  • Esophageal carcinoma
  • Proton pump inhibition

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model. / Miyashita, Tomoharu; Shah, Furhawn A.; Marti, Guy P.; Wang, Jiaai; Bonde, Pramod; Gibson, Michael K.; Ohta, Tetsuo; Montgomery, Elizabeth A; Duncan, Mark D; Harmon, John.

In: Digestive Diseases and Sciences, Vol. 56, No. 5, 05.2011, p. 1309-1314.

Research output: Contribution to journalArticle

Miyashita, Tomoharu ; Shah, Furhawn A. ; Marti, Guy P. ; Wang, Jiaai ; Bonde, Pramod ; Gibson, Michael K. ; Ohta, Tetsuo ; Montgomery, Elizabeth A ; Duncan, Mark D ; Harmon, John. / Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 5. pp. 1309-1314.
@article{67e206cb3fbe46bdaba2e96e2fcc79bd,
title = "Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model",
abstract = "Background: The role of proton pump inhibitors in Barrett's metaplasia and esophageal adenocarcinoma has been an area of controversy. Aims: We evaluated the effectiveness of the proton pump inhibitor rabeprazole as a chemoprevention agent in a surgical rat reflux model of esophageal cancer. Methods: The rat reflux model was created by performing a jejuno-esophagostomy on Sprague-Dawley rats. The surgery promoted the reflux of gastro-duodenal contents into the esophagus. Rabeprazole sodium (Eisai, Tokyo, Japan) was dissolved in 0.9{\%} physiological saline to a desired concentration of 1.5{\%} (W/V). Beginning 4 weeks post-surgery, all animals were administered either 0.2 ml per 100 g body weight injections of rabeprazole or equivalent injections of saline 3 days per week into the subcutaneous tissue of the back. Forty animals were killed 40 weeks after surgery and their esophagi were examined. Of these, 23 were included in the control group, while the remaining 17 were subjected to rabeprazole. Results: While 74{\%} (17/23) of the controls developed esophageal cancer, animals administered rabeprazole had an incidence of cancer of 29{\%} (5/17) (p <0.05, Fisher's exact test). Barrett's metaplasia was found on 100{\%} (23/23) of the rats in the placebo group, but there was a protective effect in the rabeprazole group with 65{\%} (11/17) of the rats displaying signs of Barrett's metaplasia (p <0.05, Fisher's exact test). All of the rats developed proliferative hyperplasia. Conclusions: Rabeprazole protected against the development of esophageal cancer in a clinically relevant surgical reflux model. Rabeprazole warrants further investigation for potential clinical use as a chemoprevention agent.",
keywords = "Barrett's metaplasia, Cancer prevention, Esophageal carcinoma, Proton pump inhibition",
author = "Tomoharu Miyashita and Shah, {Furhawn A.} and Marti, {Guy P.} and Jiaai Wang and Pramod Bonde and Gibson, {Michael K.} and Tetsuo Ohta and Montgomery, {Elizabeth A} and Duncan, {Mark D} and John Harmon",
year = "2011",
month = "5",
doi = "10.1007/s10620-010-1465-1",
language = "English (US)",
volume = "56",
pages = "1309--1314",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "5",

}

TY - JOUR

T1 - Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model

AU - Miyashita, Tomoharu

AU - Shah, Furhawn A.

AU - Marti, Guy P.

AU - Wang, Jiaai

AU - Bonde, Pramod

AU - Gibson, Michael K.

AU - Ohta, Tetsuo

AU - Montgomery, Elizabeth A

AU - Duncan, Mark D

AU - Harmon, John

PY - 2011/5

Y1 - 2011/5

N2 - Background: The role of proton pump inhibitors in Barrett's metaplasia and esophageal adenocarcinoma has been an area of controversy. Aims: We evaluated the effectiveness of the proton pump inhibitor rabeprazole as a chemoprevention agent in a surgical rat reflux model of esophageal cancer. Methods: The rat reflux model was created by performing a jejuno-esophagostomy on Sprague-Dawley rats. The surgery promoted the reflux of gastro-duodenal contents into the esophagus. Rabeprazole sodium (Eisai, Tokyo, Japan) was dissolved in 0.9% physiological saline to a desired concentration of 1.5% (W/V). Beginning 4 weeks post-surgery, all animals were administered either 0.2 ml per 100 g body weight injections of rabeprazole or equivalent injections of saline 3 days per week into the subcutaneous tissue of the back. Forty animals were killed 40 weeks after surgery and their esophagi were examined. Of these, 23 were included in the control group, while the remaining 17 were subjected to rabeprazole. Results: While 74% (17/23) of the controls developed esophageal cancer, animals administered rabeprazole had an incidence of cancer of 29% (5/17) (p <0.05, Fisher's exact test). Barrett's metaplasia was found on 100% (23/23) of the rats in the placebo group, but there was a protective effect in the rabeprazole group with 65% (11/17) of the rats displaying signs of Barrett's metaplasia (p <0.05, Fisher's exact test). All of the rats developed proliferative hyperplasia. Conclusions: Rabeprazole protected against the development of esophageal cancer in a clinically relevant surgical reflux model. Rabeprazole warrants further investigation for potential clinical use as a chemoprevention agent.

AB - Background: The role of proton pump inhibitors in Barrett's metaplasia and esophageal adenocarcinoma has been an area of controversy. Aims: We evaluated the effectiveness of the proton pump inhibitor rabeprazole as a chemoprevention agent in a surgical rat reflux model of esophageal cancer. Methods: The rat reflux model was created by performing a jejuno-esophagostomy on Sprague-Dawley rats. The surgery promoted the reflux of gastro-duodenal contents into the esophagus. Rabeprazole sodium (Eisai, Tokyo, Japan) was dissolved in 0.9% physiological saline to a desired concentration of 1.5% (W/V). Beginning 4 weeks post-surgery, all animals were administered either 0.2 ml per 100 g body weight injections of rabeprazole or equivalent injections of saline 3 days per week into the subcutaneous tissue of the back. Forty animals were killed 40 weeks after surgery and their esophagi were examined. Of these, 23 were included in the control group, while the remaining 17 were subjected to rabeprazole. Results: While 74% (17/23) of the controls developed esophageal cancer, animals administered rabeprazole had an incidence of cancer of 29% (5/17) (p <0.05, Fisher's exact test). Barrett's metaplasia was found on 100% (23/23) of the rats in the placebo group, but there was a protective effect in the rabeprazole group with 65% (11/17) of the rats displaying signs of Barrett's metaplasia (p <0.05, Fisher's exact test). All of the rats developed proliferative hyperplasia. Conclusions: Rabeprazole protected against the development of esophageal cancer in a clinically relevant surgical reflux model. Rabeprazole warrants further investigation for potential clinical use as a chemoprevention agent.

KW - Barrett's metaplasia

KW - Cancer prevention

KW - Esophageal carcinoma

KW - Proton pump inhibition

UR - http://www.scopus.com/inward/record.url?scp=79955595807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955595807&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1465-1

DO - 10.1007/s10620-010-1465-1

M3 - Article

VL - 56

SP - 1309

EP - 1314

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -